https://www.solosoft.dev/tags/isotope-supply/Recent content in Isotope Supply on SoloSoftHugoen-ushttps://www.solosoft.dev/trends/2026-04-23-we-need-more-radioactive-drugs-can-we-make-them-fr/Mon, 01 Jan 0001 00:00:00 +0000https://www.solosoft.dev/trends/2026-04-23-we-need-more-radioactive-drugs-can-we-make-them-fr/<h2 id="why-have-radiopharmaceuticals-suddenly-become-a-must-win-arena-for-pharma">Why Have Radiopharmaceuticals Suddenly Become a Must-Win Arena for Pharma?</h2> <p><strong>Answer in a Nutshell: The side effects of traditional chemotherapy and radiotherapy have driven the rise of precision medicine. Radiopharmaceuticals use targeting molecules to carry radioactive isotopes directly to cancer cells, reducing systemic toxicity. Clinical trials show efficacy against advanced prostate cancer and neuroendocrine tumors, with the market projected to exceed $30 billion by 2030.</strong></p> <p>Over the past decade, radioligand therapy has evolved from an academic concept to a clinical mainstay. Novartis&rsquo;s Lutathera and Pluvicto have received FDA approval, with combined annual sales exceeding $2 billion. The core technology involves attaching radioactive isotopes (e.g., lutetium-177, actinium-225) to specific ligands that home in on receptors on cancer cells, releasing radiation to destroy tumors.</p>